Skip to content
OpenCapital
Get started

Corcept Therapeutics CORT Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Incyte logo
IncyteINCY
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+21.1%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-452%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-464%

Valuation

See full
Market cap$8.58B-64.4%
Enterprise value$8.48B-65.0%
P/E181.2×+1.3×
P/S11.2×-24.0×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.2pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0×0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corcept Therapeutics's proceeds from issuance of common stock relating to employee stock plans?
Corcept Therapeutics (CORT) reported proceeds from issuance of common stock relating to employee stock plans of $2.54M in Q1 2026.
How has Corcept Therapeutics's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
Corcept Therapeutics's proceeds from issuance of common stock relating to employee stock plans increased by 47.9% year-over-year, from $1.72M to $2.54M.
What is the long-term trend for Corcept Therapeutics's proceeds from issuance of common stock relating to employee stock plans?
Over 3 years (2022 to 2025), Corcept Therapeutics's proceeds from issuance of common stock relating to employee stock plans has grown at a 113.4% compound annual growth rate (CAGR), from $990K to $9.62M.